[
  {
    "ts": null,
    "headline": "NYLI Balanced Fund Q1 2025 Commentary",
    "summary": "The NYLI Balanced Fund outperformed its benchmark only marginally this quarter but landed solidly amongst the top quartile of funds within Morningstarâs Moderate Allocation category.",
    "url": "https://finnhub.io/api/news?id=af9090335462de0ade490b12852e111498cc7938f55c80e909064d6a99404ca0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751586300,
      "headline": "NYLI Balanced Fund Q1 2025 Commentary",
      "id": 135743781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201143780/image_2201143780.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The NYLI Balanced Fund outperformed its benchmark only marginally this quarter but landed solidly amongst the top quartile of funds within Morningstarâs Moderate Allocation category.",
      "url": "https://finnhub.io/api/news?id=af9090335462de0ade490b12852e111498cc7938f55c80e909064d6a99404ca0"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)’s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to reduce the risk of sexually acquired HIV in adults and adolescents weighing a minimum of 35 […]",
    "url": "https://finnhub.io/api/news?id=9baa41d46fa516537042ea8b1661537c2f8d86ee27804077d413d4c9a27b8bcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751525249,
      "headline": "Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)",
      "id": 135735854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)’s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to reduce the risk of sexually acquired HIV in adults and adolescents weighing a minimum of 35 […]",
      "url": "https://finnhub.io/api/news?id=9baa41d46fa516537042ea8b1661537c2f8d86ee27804077d413d4c9a27b8bcf"
    }
  }
]